Pamela J Mclean

List of Publications by Year
in descending order

102 papers	18,343 citations	31976 53 h-index	32842 100 g-index
104 all docs	104 docs citations	104 times ranked	24466 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
3	Gaucher Disease Glucocerebrosidase and Î±-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell, 2011, 146, 37-52.	28.9	1,097
4	Sirtuin 2 Inhibitors Rescue Î±-Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science, 2007, 317, 516-519.	12.6	995
5	Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration, 2012, 7, 42.	10.8	708
6	Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy. Journal of Neuroscience, 2005, 25, 7278-7287.	3.6	524
7	Hsp70 Reduces Î±-Synuclein Aggregation and Toxicity. Journal of Biological Chemistry, 2004, 279, 25497-25502.	3.4	460
8	Formation of Toxic Oligomeric Î±-Synuclein Species in Living Cells. PLoS ONE, 2008, 3, e1867.	2.5	354
9	Direct quantification of CSF Î±-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 2008, 213, 315-325.	4.1	334
10	TorsinA and heat shock proteins act as molecular chaperones: suppression of Î±â€synuclein aggregation. Journal of Neurochemistry, 2002, 83, 846-854.	3.9	318
11	Distinct Roles<i>In Vivo</i>for the Ubiquitinâ€“Proteasome System and the Autophagyâ€“Lysosomal Pathway in the Degradation of Î±-Synuclein. Journal of Neuroscience, 2011, 31, 14508-14520.	3.6	311
12	The Co-chaperone Carboxyl Terminus of Hsp70-interacting Protein (CHIP) Mediates Î±-Synuclein Degradation Decisions between Proteasomal and Lysosomal Pathways. Journal of Biological Chemistry, 2005, 280, 23727-23734.	3.4	298
13	Targeted Overexpression of Human Î±-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1149-1158.	1.7	295
14	Heatâ€shock protein 70 modulates toxic extracellular Î±â€synuclein oligomers and rescues transâ€synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.5	276
15	Î±â€Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology, 2013, 73, 155-169.	5.3	255
16	Pharmacological promotion of inclusion formation: A therapeutic approach for Huntingtonâ€™s and Parkinsonâ€™s diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4246-4251.	7.1	244
17	Membrane Association and Protein Conformation of Î±-Synuclein in Intact Neurons. Journal of Biological Chemistry, 2000, 275, 8812-8816.	3.4	219
18	Alpha-synuclein and tau: teammates in neurodegeneration?. Molecular Neurodegeneration, 2014, 9, 43.	10.8	216

#	Article	IF	Citations
19	Protein degradation pathways in Parkinsonâ€™s disease: curse or blessing. Acta Neuropathologica, 2012, 124, 153-172.	7.7	213
20	Î±-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling. Current Biology, 2014, 24, 2319-2326.	3.9	210
21	Notch1 inhibits neurite outgrowth in postmitotic primary neurons. Neuroscience, 1999, 93, 433-439.	2.3	206
22	Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiology of Disease, 2015, 78, 172-195.	4.4	200
23	SIRT1 Protects against Î±-Synuclein Aggregation by Activating Molecular Chaperones. Journal of Neuroscience, 2012, 32, 124-132.	3.6	191
24	Small heat shock proteins protect against Î±-synuclein-induced toxicity and aggregation. Biochemical and Biophysical Research Communications, 2006, 351, 631-638.	2.1	180
25	Geldanamycin induces Hsp70 and prevents Î±-synuclein aggregation and toxicity in vitro. Biochemical and Biophysical Research Communications, 2004, 321, 665-669.	2.1	178
26	Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry, 2007, 100, 070214184024010-???.	3.9	164
27	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent Î±-Synuclein Oligomer Formation and Rescue Î±-Synuclein-Induced Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 849-857.	2.5	162
28	Tyrosine and serine phosphorylation of Î±-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. Journal of Clinical Investigation, 2009, 119, 3257-65.	8.2	158
29	CHIP Targets Toxic Î±-Synuclein Oligomers for Degradation. Journal of Biological Chemistry, 2008, 283, 17962-17968.	3.4	155
30	Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism and Related Disorders, 2016, 22, S106-S110.	2.2	124
31	Ubiquitinylation of Î±-Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5). PLoS ONE, 2011, 6, e14695.	2.5	119
32	Mutual exacerbation of peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± deregulation and Î±â€synuclein oligomerization. Annals of Neurology, 2015, 77, 15-32.	5.3	112
33	Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Molecular Neurodegeneration, 2020, 15, 5.	10.8	112
34	Î±-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 515-524.	1.7	111
35	Alpha-synuclein aggregation involves a bafilomycin A₁-sensitive autophagy pathway. Autophagy, 2012, 8, 754-766.	9.1	111
36	A Close Association of TorsinA and Î±-Synuclein in Lewy Bodies. American Journal of Pathology, 2001, 159, 339-344.	3.8	110

#	Article	IF	Citations
37	Aspartate Mutations in Presenilin and Î³-Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling. Journal of Neurochemistry, 2002, 75, 583-593.	3.9	101
38	Increased Immune Activation by Pathologic Î±â€Synuclein in Parkinson's Disease. Annals of Neurology, 2019, 86, 593-606.	5.3	95
39	Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. Journal of Neurochemistry, 2009, 109, 838-845.	3.9	91
40	Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Frontiers in Neuroscience, 2017, 11, 172.	2.8	91
41	APOE4 exacerbates Î±-synuclein pathology and related toxicity independent of amyloid. Science Translational Medicine, 2020, 12, .	12.4	90
42	Detection of novel intracellular Oâ€synuclein oligomeric species by fluorescence lifetime imaging. FASEB Journal, 2006, 20, 2050-2057.	0.5	82
43	Chaperones in Neurodegeneration. Journal of Neuroscience, 2015, 35, 13853-13859.	3.6	81
44	CRISPR/Cas9 editing of APP C-terminus attenuates Î²-cleavage and promotes Î±-cleavage. Nature Communications, 2019, 10, 53.	12.8	81
45	Cellular models of alphaâ€synuclein toxicity and aggregation. Journal of Neurochemistry, 2019, 150, 566-576.	3.9	75
46	Impaired endo-lysosomal membrane integrity accelerates the seeding progression of Î±-synuclein aggregates. Scientific Reports, 2017, 7, 7690.	3.3	73
47	Mapping of the Î±4 subunit gene (GABRA4) to human chromosome 4 defines an Î±2â€"Î±4â€"Î²1â€"Î³1 gene cluster: further evidence that modern GABAA receptor gene clusters are derived from an ancestral cluster. Genomics, 1995, 26, 580-586.	2.9	69
48	The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons. Molecular Brain Research, 1999, 69, 273-280.	2.3	69
49	Interaction of Î±-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. Journal of Neurochemistry, 2001, 77, 929-934.	3.9	65
50	Characterization of Oligomer Formation of Amyloid-Î² Peptide Using a Split-luciferase Complementation Assay. Journal of Biological Chemistry, 2011, 286, 27081-27091.	3.4	65
51	Molecular Chaperones in Parkinson's Disease â€" Present and Future. Journal of Parkinson's Disease, 2011, 1, 299-320.	2.8	63
52	Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease, 2008, 29, 515-528.	4.4	62
53	Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinsonâ€™s disease. Gut Microbes, 2021, 13, 1866974.	9.8	61
54	Dopamine-Induced Conformational Changes in Alpha-Synuclein. PLoS ONE, 2009, 4, e6906.	2.5	59

#	Article	IF	Citations
55	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1058-1066.	1.7	55
56	Clinical and biochemical correlates of insoluble Î±-synuclein in dementia with Lewy bodies. Acta Neuropathologica, 2006, 111, 101-108.	7.7	55
57	Targeting heat shock proteins to modulate Î±-synuclein toxicity. Therapeutic Advances in Neurological Disorders, 2014, 7, 33-51.	3.5	53
58	Converse modulation of toxic Î±-synuclein oligomers in living cells by Nâ€²-benzylidene-benzohydrazide derivates and ferric iron. Biochemical and Biophysical Research Communications, 2010, 391, 461-466.	2.1	52
59	Alpha-synucleinâ€™s degradation in vivo. Autophagy, 2012, 8, 281-283.	9.1	50
60	Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications, 2013, 1, 6.	5.2	49
61	In Vivo Imaging of Î±-Synuclein in Mouse Cortex Demonstrates Stable Expression and Differential Subcellular Compartment Mobility. PLoS ONE, 2010, 5, e10589.	2.5	49
62	14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic Î±-Synuclein. Journal of Neuroscience, 2018, 38, 8211-8232.	3.6	48
63	Molecular Chaperones and Co-Chaperones in Parkinson Disease. Neuroscientist, 2012, 18, 589-601.	3.5	47
64	Convergence of pathology in dementia with Lewy bodies and Alzheimerâ€™s disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain, 2014, 137, 1958-1970.	7.6	44
65	A single amino acid substitution differentiates Hsp70-dependent effects on Î±-synuclein degradation and toxicity. Biochemical and Biophysical Research Communications, 2004, 325, 367-373.	2.1	43
66	The neural chaperone proSAAS blocks Î±-synuclein fibrillation and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4708-15.	7.1	38
67	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not Î±-Synuclein-Induced Neuronal Cell Loss. PLoS ONE, 2014, 9, e86048.	2.5	35
68	Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochemical Research, 2003, 28, 1683-1691.	3.3	34
69	Caspase-3-derived C-terminal Product of Synphilin-1 Displays Antiapoptotic Function via Modulation of the p53-dependent Cell Death Pathway. Journal of Biological Chemistry, 2006, 281, 11515-11522.	3.4	34
70	Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiology of Aging, 2015, 36, 1209-1220.	3.1	32
71	Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. Acta Neuropathologica, 2001, 102, 329-334.	7.7	31
72	An alternatively spliced form of rodent Î±-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in Î±-synuclein aggregation. Neuroscience Letters, 2002, 323, 219-223.	2.1	31

#	Article	IF	Citations
73	Targeting Î±-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opinion on Therapeutic Targets, 2015, 19, 589-603.	3.4	31
74	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
75	Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilinâ€associated Î³â€Secretase Activity. Annals of the New York Academy of Sciences, 2000, 920, 223-226.	3.8	29
76	Î±-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration, 2015, 10, 66.	10.8	29
77	Molecular chaperones in Parkinson's disease--present and future. Journal of Parkinson's Disease, 2011, 1, 299-320.	2.8	29
78	Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Regulates the Stability and Function of GluA1 Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) Receptor in Neurons. PLoS ONE, 2014, 9, e113237.	2.5	28
79	Proaggregant nuclear factor(s) trigger rapid formation of Î±-synuclein aggregates in apoptotic neurons. Acta Neuropathologica, 2016, 132, 77-91.	7.7	27
80	Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine, 2018, 29, 13-22.	6.1	26
81	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	6.4	26
82	Transmission of Soluble and Insoluble Î±-Synuclein to Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1158-1169.	1.7	25
83	A Minimal Promoter for the GABAA Receptor Î±6-Subunit Gene Controls Tissue Specificity. Journal of Neurochemistry, 2008, 74, 1858-1869.	3.9	24
84	Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathologica Communications, 2017, 5, 51.	5.2	24
85	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinsonâ€™s Disease. Molecular Imaging and Biology, 2013, 15, 585-595.	2.6	21
86	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. European Journal of Neurology, 2015, 22, 1323-1325.	3.3	21
87	Histones facilitate Î±-synuclein aggregation during neuronal apoptosis. Acta Neuropathologica, 2017, 133, 547-558.	7.7	20
88	<i>In Vivo</i> Detection of Extracellular Adenosine Triphosphate in a Mouse Model of Traumatic Brain Injury. Journal of Neurotrauma, 2021, 38, 655-664.	3.4	16
89	Direct Visualization of CHIP-Mediated Degradation of Alpha-Synuclein In Vivo: Implications for PD Therapeutics. PLoS ONE, 2014, 9, e92098.	2.5	14
90	Transmission of Soluble and Insoluble Î±-Synuclein to Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1158-1169.	1.7	14

#	Article	IF	Citations
91	Drug Targets from Genetics: Alpha-Synuclein. CNS and Neurological Disorders - Drug Targets, 2011, 10, 712-723.	1.4	9
92	Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization. Journal of Neurology and Neuromedicine, 2016, 1, 28-30.	0.9	9
93	Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2022, 17, 16.	10.8	8
94	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (Î±-syn) oligomerization and secretion. Aging, 2017, 9, 1677-1697.	3.1	7
95	A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. Frontiers in Neuroscience, 2015, 9, 511.	2.8	5
96	Studying protein degradation pathways in vivo using a cranial window-based approach. Methods, 2011, 53, 194-200.	3.8	4
97	Intracellular formation of Î±-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochemical and Biophysical Research Communications, 2016, 477, 76-82.	2.1	4
98	Untangling a Role for Tau in Synucleinopathies. Biological Psychiatry, 2015, 78, 666-667.	1.3	2
99	Lewy body dementia. , 2017, , 175-198.		2
100	Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. RSC Drug Discovery Series, 2013, , 392-413.	0.3	1
101	Cellular and Molecular Mechanisms Underlying Parkinsonâ€™s Disease: The Role of Molecular Chaperones. , 2008, , 51-68.		1
102	Dementia with Lewy bodies. , 2002, , 267-282.		0